Argenx SE logo

ARGX - Argenx SE Share Price

$154.21 0.9  0.6%

Last Trade - 6:14pm

Sector
Healthcare
Size
Large Cap
Market Cap £5.01bn
Enterprise Value £4.21bn
Revenue £75.4m
Position in Universe 1032nd / 6416
Bullish
Bearish
Unlock ARGX Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

ARGX Revenue Unlock ARGX Revenue

Net Income

ARGX Net Income Unlock ARGX Revenue

Normalised EPS

ARGX Normalised EPS Unlock ARGX Revenue

PE Ratio Range

ARGX PE Ratio Range Unlock ARGX Revenue

Dividend Yield Range

ARGX Dividend Yield Range Unlock ARGX Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ARGX EPS Forecasts Unlock ARGX Revenue
Profile Summary

argenx SE, formerly arGEN X BV, is the Netherlands-based biopharmaceutical company. It creates and develops a pipeline of differentiated antibody therapeutics using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes: ARGX-110, an antibody for heme malignancies and solid tumors, which modulates functions of tumor such as cell proliferation and survival; ARGX-111, an antagonist of c-Met, a receptor tyrosine kinase involved in cell proliferation, angiogenesis and metastasis in multiple solid tumors; ARGX-112, an antigen which targets atopic dermatitis by neutralization of IL-20 and IL-22 (interleukin) mediated signaling through blockade of their common receptor, among others.

Directors
Last Annual December 31st, 2018
Last Interim September 30th, 2019
Public Since July 10, 2014
No. of Shareholders: n/a
No. of Employees: 105
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market (Dual Listing)
Shares in Issue 42,707,527
Free Float (0.0%)
Eligible for
ISAs
SIPPs
Address Willemstraat 5, BREDA, 4811 AH, Netherlands
Web http://www.argen-x.com
Phone +31 76 3030488
Contact ()
Auditors Deloitte Accountants B.V.
ARGX Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for ARGX
Upcoming Events for ARGX
Wednesday 6th May, 2020 Estimate
argenx SE Annual Shareholders Meeting
Similar to ARGX
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.